Analyst upgrades:

• Piper upgraded Intel (NASDAQ: INTC) to Buy from Neutral to reflect the company's strong competitive position and low valuation. The firm does not expect Intel to miss Q3 estimates.
  
• Goldman upgraded shares of Deutsche Telecom (NYSE: DT) to Buy from Neutral and added the stock to the Conviction Buy List as they believe the dividend is well covered.
  
• Wachovia upgraded Landstar System (NASDAQ: LSTR) to Outperform from Market Perform on valuation and potential near-term catalysts from hurricane-related activities.
• Abercrombie & Fitch (NYSE: ANF) was raised to Outperform from Market Perform at Friedman Billings.
  
• Research in Motion (NASDAQ: RIMM) was upgraded at JMP Securities to Outperform from Market Perform.
  
• Baird lifted Wells Fargo (NYSE: WFC) to Neutral from Underperform.

Analyst downgrades:

• Jefferies downgraded VCA Antech (NASDAQ: WOOF) to Underperform from Buy as they believe reduced consumer spending and rising unemployment levels will hurt the company's hospital and lab volumes in FY09. The company's target was lowered to $25 from $35.
  
• Oppenheimer downgraded shares of Total System (NYSE: TSS) to Perform from Outperform to reflect the challenging macro environment and the customer portfolio risk from bank consolidation.

MOST NOTEWORTHY: Mueller Water, ASM International and Kensey Nash were today's noteworthy upgrades:

• Baird upgraded shares of Mueller Water (NYSE: MWA) to Outperform from Neutral following recent channel checks, as they believe the company has seen a cyclical trough in earnings and downside is limited at current levels. The company's target was raised to $12 from $9.
  
• Jefferies upgraded shares of ASM International (NASDAQ: ASMI) to Buy from Hold as they believe a break-up is likely following bids for the company's front-end business.
  
• Susquehanna said Kensey Nash's (NASDAQ: KNSY) sale of its endovascular products division was the best outcome and will allow the company to focus on being a pure-play OEM biomaterials platform company. Shares were upgraded to Positive from Neutral.

OTHER UPGRADES:

• Goldman added Vistaprint (NASDAQ: VPRT) to the Conviction Buy List.
  
• UBS upgraded Smith & Nephew (NYSE: SNN) to Buy from Neutral.
  
• BorgWarner (NYSE: BWA) was raised to Overweight from Equal Weight at Lehman.

MOST NOTEWORTHY: Smith & Nephew, British Sky Broadcasting and Electronic Data Systems were today's noteworthy downgrades:

• Smith & Nephew (NYSE: SNN) was cut to Underweight from Neutral at JP Morgan, citing deteriorating fundamentals in several of SNN's key business lines.
  
• Goldman removed British Sky Broadcasting (NYSE: BSY) from its Conviction Buy List and said shares continue to trade at all-time low multiples and that the timing with Sky-Virgin dispute remains unclear. Shares remain Buy rated.
  
• Friedman Billings downgraded Electronic Data Systems (NYSE: EDS) to Market Perform from Outperform based on valuation following the Hewlett-Packard (NYSE: HPQ) news.

OTHER DOWNGRADES:

• Goldman downgraded J Sainsbury (OTC: JSAIY) to Neutral from Buy and removed shares from the Conviction Buy List.
  
• Goldman also removed Hewlett-Packard from its Conviction Buy List.
  
• Citigroup cut BearingPoint (NYSE: BE) to Hold from Buy.
  
• Wachovia downgraded LHC Group (NASDAQ: LHCG) to Market Perform from Outperform.

MOST NOTEWORTHY: SunPower, Evergreen Solar and Abbott Lab were today's noteworthy initiations:

• Citigroup believes SunPower (NASDAQ: SPWR) is faced with high cell production costs, its silicon cost and installation cost advantages are increasingly commoditized and finds the risk/reward even at current levels. Shares were initiated with a Hold rating and $105 target.
  
• Citigroup believes Evergreen Solar (NASDAQ: ESLR) faces significant financing requirements over the next few years, making it difficult to see a sustained period of EPS growth beyond the $1 range. The firm sees downside to $5/share. Shares were assumed with a Sell rating and $8 target.
  
• UBS started Abbott Lab (NYSE: ABT) with a Buy rating and $61 target. The firm is positive on Humira potential growth and expects Xience to drive vascular operating margins to positive.

OTHER INITIATIONS:

• Lazard initiated Cree (NASDAQ: CREE) and Rubicon Tech (NASDAQ: RBCN) with Hold ratings.
  
• BMO Capital started Smith & Nephew (NYSE: SNN) with an Outperform rating and $70 target.

MOST NOTEWORTHY: BP, LMI Aerospace and Smith & Nephew were among today's noteworthy upgrades:

• Credit Suisse upgraded BP (NYSE: BP) following the company's strong Q1 report.
  
• Wachovia upgraded LMI Aerospace (NASDAQ: LMIA) based on valuation and potential catalysts that include a production rate hike decision on the Boeing 737, an option on the 767 wing modification program, and Q1 earnings.
  
• Wachovia upgraded Smith & Nephew (NYSE: SNN) based on growth opportunities, strong reconstruction product cycle, and potential share gains, among other reasons.

OTHER UPGRADES:

• UBS upgraded James River Coal Co. (NASDAQ: JRCC) based on higher long-term coal prices.
  
• Merriman upgraded Denny's Corp. (NASDAQ: DENN) because they believe that franchise growth initiative will reinvigorate the franchisees and put the company in a better position to beat estimates over the next year. The firm thinks investors need to refocus on the company's core operating profitability.

Smith & Nephew plc (NYSE:SNN) announced the acquisition this morning of Swiss company Plus Orthopedics for $889 million in cash. This will solidify Smith & Nephew's position as the number 4 global player. The other three major firms are Stryker Corp. (NYSE:SYK), Zimmer Holdings (NYSE:ZMH), and soon to be acquired Biomet Inc. (NASDAQ:BMET). Biomet is undergoing due diligence by a group of private equity firms led by the Blackstone Group. The transaction is expected to close by October of this year.

The orthopedic sector has the wind at its back. The approval process for an orthopedic device is rigorous, but not as lengthy as the cardiac device sector. The marketplace is global in nature and the demographics are about to enter the sweet spot.

With 78 million U.S. baby boomers alone, and another 80 million-plus baby boomers in the European markets, the aging of this group is ripe for the sector. New hips, knees, elbows and shoulders will see record recipients as each year unfolds. Besides the basic joint-replacement products, the spinal sector is also expected to see massive growth. Minimally invasive surgical procedures are expanding the addressable market as the risk profile for such surgeries is significantly less. The dread of osteoporosis affects nearly 700,000 women in the United States alone.